Name (Synonyms) | Correlation | |
---|---|---|
drug1121 | Hydroxychloroquine combined with Azithromycin Wiki | 1.00 |
drug924 | Favipiravir (3200 mg + 1200 mg) Wiki | 1.00 |
drug927 | Favipiravir (3600 mg + 1600 mg) Wiki | 1.00 |
drug925 | Favipiravir (3200 mg + 1200 mg) combined with Azithromycin Wiki | 1.00 |
drug2765 | blood sample Wiki | 0.41 |
drug1086 | Hydroxychloroquine Wiki | 0.10 |
Name (Synonyms) | Correlation | |
---|---|---|
D004630 | Emergencies NIH | 0.19 |
D003141 | Communicable Diseases NIH | 0.09 |
D007239 | Infection NIH | 0.06 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
This is an open-label, multicenter, parallel-group, randomized, phase III trial that evaluates the efficacy and safety of hydroxychloroquine and favipiravir in the treatment of patients with possible or confirmed COVID-19 observed within the last 5 days. 1000 patients will be randomized in 2:1:2:2:2:1 ratio and divided into six groups.
Description: The evaluation of recovery (discharge) period until 14th day after administration.
Measure: Time to recovery (discharge) Time: 14 daysDescription: The evaluation of decrease in viral load until 14th day after administration.
Measure: Decrease in viral load Time: 14 daysDescription: Number/characteristics of Adverse Event (AE), Serious Adverse Event (SAE) and discontinuation of treatment due to study drug from baseline until the end of study
Measure: Adverse Event (AE), Serious Adverse Event (SAE) and discontinuation of treatment Time: 14 daysDescription: Clinical evaluation of occurrence of lymphopenia from baseline until the end of study.
Measure: Frequency of occurrence of lymphopenia from baseline Time: 14 daysDescription: Clinical evaluation of occurrence of thrombocytopenia from baseline until the end of study.
Measure: Frequency of occurrence of thrombocytopenia from baseline Time: 14 daysDescription: Clinical evaluation of ALT levels from baseline until the end of study.
Measure: Changes in alanine aminotransferase (ALT) levels from baseline Time: 14 daysDescription: Clinical evaluation of AST levels from baseline until the end of study.
Measure: Changes in aspartate aminotransferase (AST) levels from baseline Time: 14 daysDescription: Clinical evaluation of CRP levels from baseline until the end of study.
Measure: Changes in C-reactive protein (CRP) levels from baseline Time: 14 daysDescription: Clinical evaluation of D-dimer levels from baseline until the end of study.
Measure: Changes in level of D-dimer levels from baseline Time: 14 daysDescription: Clinical evaluation of PT values for blood to coagulate from baseline until the end of study.
Measure: Changes in prothrombin time (PT) values from baseline Time: 14 daysDescription: Clinical evaluation of PTT values for blood to coagulate from baseline until the end of study.
Measure: Changes in partial thromboplastin time (PTT) values from baseline Time: 14 daysDescription: Clinical evaluation of systolic and diastolic blood pressure levels from baseline until the end of study.
Measure: Changes in blood pressure from baseline Time: 14 daysDescription: Clinical evaluation of respiratory rate levels from baseline until the end of study.
Measure: Changes in respiratory rate from baseline Time: 14 daysDescription: Clinical evaluation of pulse oxymetry levels from baseline until the end of study.
Measure: Changes in pulse oxymetry from baseline Time: 14 daysDescription: Clinical evaluation of changes in fever from baseline until the end of study.
Measure: Changes in fever from baseline Time: 14 days